Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

About Exact Sciences Corp. NOTE: Exact Sciences, Cologuard and Cologuard Plus are ... Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form ...

Exact Sciences' Q3 earnings report has led to a ... Exact's main sources of revenues are its Cologuard test, a "patient-friendly, non-invasive stool-based DNA screening test that utilizes a ...

NOTE: Exact Sciences, Cologuard and Cologuard Plus are trademarks ... Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and ...

For more information about the Cologuard test, visit Cologuard.com. Rx only. About Exact Sciences Corp. This news ... of our most recent Annual Report on Form 10-K and any subsequent Quarterly ...

The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common stock. (4) Represents impairment charges on the Company’s long-lived assets.